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Abstract
CD68 is a member of the lysosome associated membrane protein (LAMP) family that is restricted in its expression to cells of
the monocyte/macrophage lineage. This lineage restriction includes osteoclasts, and, while previous studies of CD68 in
macrophages and dendritic cells have proposed roles in lipid metabolism, phagocytosis, and antigen presentation, the
expression and function of CD68 in osteoclasts have not been explored. In this study, we investigated the expression and
localization of CD68 in macrophages and osteoclasts in response to the monocyte/macrophage-colony stimulating factor
(M-CSF) and the receptor activator of NF-kB ligand (RANKL). We found that M-CSF stimulates CD68 expression and RANKL
alters the apparent molecular weight of CD68 as measured by Western immunoblotting. In addition, we explored the
significance of CD68 expression in osteoclasts by generating mice that lack expression of CD68. These mice have increased
trabecular bone, and in vitro assessment of CD68
2/2 osteoclasts revealed that, in the absence of CD68, osteoclasts
demonstrate an accumulation of intracellular vesicle-like structures, and do not efficiently resorb bone. These findings
demonstrate a role for CD68 in the function of osteoclasts, and future studies will determine the mechanistic nature of the
defects seen in CD68
2/2 osteoclasts.
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Introduction
CD68, also known as macrosialin, is a heavily glycosylated
LAMP family member that is commonly used as a histological
marker of macrophage lineage cells. Indeed, CD68 expression can
be found in the resident macrophages of multiple tissues such as
microglia in the brain, Kupffer cells in the liver, and bone marrow
macrophages (BMMs) [1–3]. Furthermore, immunohistochemical
staining of bone tissues has demonstrated expression of CD68 in
osteoclasts, which are multinucleated, bone-resorbing giant cells of
monocyte/macrophage origin [3,4]. Infiltration of CD68-positive
cells is also used clinically as a marker of inflammation and tumor
progression [5–8]. The apparent monocyte/macrophage lineage
specificity of CD68 expression has not only led to its routine use in
histological identification of macrophages, but to the proposed use
of the CD68 promoter to specifically direct transgene expression in
both in vitro and in vivo model systems and gene therapy [9–11].
Though both CD68 protein and gene have been and continue to
be used as tools in both research and clinical settings, studies of the
physiological function(s) of CD68 remain inconclusive.
Despite the lack of a specific, defined role for CD68 in cells,
studies of the characteristics and regulation of the CD68 gene and
protein have inspired many of the early studies into its function.
Ramprasad et al. demonstrated via ligand blotting and affinity
purification experiments that CD68 is capable of binding oxidized
low density lipoprotein (oxLDL) and can be detected on the surface
of macrophages [12–14]. This oxLDL binding property was found
by multiple groups, and, recently, the oxLDL binding properties of
CD68 were exploited in a pre-clinical model wherein atheroscle-
rotic lesion progression was retarded by application of a soluble Fc
receptor-CD68 fusion protein [15,16]. The binding of oxLDL by
CD68 appears to be independent of associated sugar moieties as
even deglycosylated CD68 retains much of its oxLDL binding
affinity. CD68 not only binds oxLDL, but its expression also
appears to be upregulated by oxLDL [17]. de Beer et al. found that
levelsofCD68intheliversofmicefedahighfatdietwereincreased,
and a direct effect of lipid on macrophage expression of CD68 was
confirmed by Llaverias et al. [18,19]. These studies of CD68’s
oxLDL binding affinity and its expression on the cell surface
suggested a role for CD68 in the uptake of oxLDL, and, indeed,
antibody blockage of CD68 on PMA-stimulated THP-1 monocytes
resulted in reduced binding and uptake of oxLDL [13]. However,
dsRNA-mediated silencing of CD68 expression in both primary
peritoneal macrophages and macrophage-like RAW264.7 cells
failed to reduce oxLDL binding by either cell type [18]. In addition,
it was recently determined via examination of peritoneal macro-
phages from mice lacking expression of CD68 that neither oxLDL
uptake nor microbe phagocytosis is dependant on CD68 expression
[20]. Thus, despite its accepted oxLDL binding properties, the
specific role of CD68 remains controversial, and there has been no
further demonstration of the physiological significance of CD68
expression in any cell type.
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25838Given that most studies of CD68 have focused on macrophages
and macrophage-like cell lines, we set out to examine CD68’s
expression by osteoclasts, its regulation by the osteoclastogenic
cytokines M-CSF and RANKL, and the consequences of its
genetic ablation. Here we report that loss of CD68 results in
morphological and functional defects in osteoclasts in vitro that
result in increased bone in vivo.
Results
CD68 expression during osteoclastogenesis
We first assessed the expression of CD68 by BMMs and
osteoclasts. To this end, we collected whole cell lysates from
primary mouse BMMs cultured for varying periods of time in M-
CSF alone, which maintains the macrophage characteristics of the
cells, and BMMs cultured with M-CSF and RANKL, which
induces differentiation of BMMs to osteoclasts. We found that
freshly isolated non-adherent bone marrow mononuclear cells do
not express detectible levels of CD68, and addition of M-CSF
stimulated expression of CD68 in a time-dependant manner
(Fig. 1A). Interestingly, while addition of RANKL did not result in
significantly altered levels of CD68 compared to M-CSF alone,
RANKL treatment reduced CD68’s apparent molecular weight as
measured by its migration rate during polyacrilamide gel
electrophoresis followed by Western blotting. Similar to primary
BMMs, RAW264.7 cells, which are self-sufficient in their M-CSF
receptor signaling, constitutively express CD68, and addition of
RANKL resulted in a comparable shift in CD68’s migration rate
with no significant change in expression (Fig. 1B). CD68 can be
found on the cell surface of macrophages, and this RANKL-
induced form of CD68 may be subject to altered surface
localization [21,22]. To determine whether the RANKL-induced
form of CD68 can still be detected on the surface of BMMs, we
analyzed primary BMMs treated for 72 hours with either M-CSF
alone or M-CSF and RANKL via flow cytometry. We found that
BMMs cultured with M-CSF alone express detectible levels of
CD68 on their surface, and RANKL treatment does not appear to
alter this surface expression (Fig. 1C–‘‘Surface’’). CD68 expression
was also detected intracellulalry by permeablizing cells prior to
staining (Fig. 1C–‘‘Total’’).
Cellular localization of CD68 in osteoclasts
Our own immunoblotting and published tissue immunohisto-
chemical studies have revealed expression of CD68 by osteoclasts.
We next sought to determine the intracellular distribution of
CD68 in mature, bone-adherent osteoclasts by performing
immunofluorescent staining of osteoclasts differentiated on bovine
cortical bone slices. Following staining with Alexa-488-conjugated
phalloidin for actin (green), Hoechst for nuclei (blue), and either
anti-CD68 antibody or non-immune Rat IgG2a (red), cells were
visualized using confocal microscopy (Fig. 2). Staining revealed
multiple nuclei and actin rings which are morphological features of
mature osteoclasts and intense localization of CD68 around the
periphery of the osteoclasts (Fig. 2A). CD68 could also be detected,
though less intensely, towards the central regions of the cell.
Visualization of osteoclasts along the Z-axis revealed a vertical
concentration of CD68 at the osteoclast periphery with a more
apical localization towards the center of the cell (Fig. 2B). Three-
Figure 1. CD68 is expressed by macrophages and osteoclasts. (A) CD68 and b-actin expression in mouse bone marrow suspension cells
treated with 44 ng/mL M-CSF +/2 100 ng/mL RANKL for indicated days (d). M-CSF increases expression of CD68 in a time dependant manner, and
RANKL ligand induces an accelerated gel migration rate. Image is representative of 3 independent experiments. Quantification of relative band
density is aggregate of 3 independent experiments; data shown is mean + standard deviation. (B) CD68 and b-actin expression in RAW264.7 cells with
or without 100 ng/mL RANKL treatment for indicated times. RAW264.7 cells have constitutive M-CSF-stimulated signaling and continuous expression
of CD68. RANKL induces similar changes in gel migration as those seen in primary macrophages. Image is representative of 3 independent
experiments. Quantification of relative band density is aggregate of 3 independent experiments; data shown is mean + standard deviation. (C) Flow
cytometry histograms of BMMs with 3-day treatments of 44 ng/mL M-CSF +/– 100 ng/mL RANKL with (Total) and without (Surface) permeablization
with .5% saponin. CD68 can be detected on the surface of BMMs, and neither surface nor total detectible levels of CD68 are altered by addition of
RANKL. Image is representative of 2 independent experiments.
doi:10.1371/journal.pone.0025838.g001
Expression and Function of CD68 in Osteoclasts
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25838dimensional reconstruction of imaged osteoclasts confirmed this
dome-like distribution with CD68 detected near both the bone-
apposed, basolateral, and apical surfaces along the cell periphery,
but only near the apical surface elsewhere (Fig. 2C).
Generation of CD68
2/2 mice lacking expression of CD68
Detection of CD68 on the surface of BMMs and its distribution
in osteoclasts prompted us to initiate deeper functional studies of
this protein. To further explore the role of CD68 in bone
specifically and elsewhere in general, we generated a line of mice
that lack expression of CD68. Fig. 3A–C detail the strategy of
homologous recombination within C57Bl/6J mouse embryonic
stem (ES) cells to generate the CD68 knockout allele. This
recombination event replaces exon 1, which contains CD68 start
codon, and part of exon 2 with a neomycin phosphotransferase
expression cassette (Fig. 3A–B). Male chimeras generated by
injecting the correctly targeted ES cells into albino C57Bl/6J
blastocysts were mated with albino C57Bl/6J females, and black-
coated offspring were genotyped using primers specific to the wild
type (Fig. 3B) and knockout alleles (Fig. 3C) to identify CD68
+/2





determined by PCR (Fig. 3D). CD68
2/2 mice are viable and
are born near to expected Mendelian frequencies (Table 1).
Similar to mice generated by Li et al., we observed no obvious
behavioral or gross phenotypic abnormalities in the CD68
2/2
animals [20]. We confirmed loss of CD68 expression in CD68
2/2
mice by performing immunoblots on BMM protein extracts from
mice of each genotype (Fig. 3E).




To determine the consequences of genetic ablation of CD68
o nt h eb o n em i c r o a r c h i t e c t u r ea n dt i s s u em i n e r a ld e n s i t y
(TMD), we assessed the distal femurs of 6-month-old female
mice using micro-computed tomography (mCT) and histology.
TMD is the measure of mineral content of bone tissues only, as
compared to bone mineral density (BMD), which includes
surrounding non-bone tissues. This makes TMD a more
accurate measurement of the mineral density of specific
microarchitectureal structures such as trabecular and cortical
bone[23]. Quantitative mCT data revealed that, compared to
CD68-expressing mice, mice lacking CD68 have increases in
bone volume (BV/TV) and trabecular number (Tb. N) with a
concurrent decrease in trabecular spacing (Tb. Sp.)(Fig. 4A–B).
Interestingly, there was a significant reduction in trabecular
TMD in CD68
2/2 mice compared to CD68
+/+ mice with
CD68
+/2 trending towards lower trabecular TMD (Fig. 4B);
this is intriguing because, while there is more trabecular bone in
CD68 deficient animals, the mineralization appears to be
abnormal. This decrease in TMD was not seen in cortical bone,
however, nor was cortical thickness altered (Ct. Th.) (Fig. 4C–
D). Histological examination of decalcified, TRAP-stained
femur sections similarly showed increased trabeculae in
CD68
2/2 mice and abundant bone-adherent osteoclasts in all
three genotypes (Fig. 5A–B) with no significant difference in
osteoclast numbers (N. OC/BS) (Fig. 5C). These findings of
increased trabecular bone without a corresponding decrease in
osteoclasts suggest that loss of CD68 negatively impacts
osteoclast function without reducing osteoclast numbers in vivo.
Figure 2. CD68 can be found in a dome-like pattern in osteoclasts cultured on bovine cortical bone slices. (A) BMMs were seeded onto
bone slices with 44 ng/mL M-CSF and 100 ng/mL RANKL and differentiated into osteoclasts over 4 days. Cells were fixed with 4% paraformaldehyde/
PBS and stained with Alexa-488-conjugated phalloidin (actin, green), Hoescht (nuclei, blue), and either anti-CD68 (CD68, red) or rat non-immune IgG2a
(IgG2a Merge) antibody followed by Alexa-647-conjugated anti-Rat IgG. Scale bars for CD68 staining are 40mm; scale bar for IgG2a staining is 20mm.
Images are representative of 3 independent experiments. (B) Enlarged merge image from A. * and + indicate corresponding XZ and YZ cross sectional
images, respectively. Scale bar is 40mm. Image is representative of 3 independent experiments. (C) 3-D reconstruction of osteoclast cross sectioned in
B with actin in green, nuclei in blue, and CD68 in red.
doi:10.1371/journal.pone.0025838.g002
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embedded trichrome-stained sections demonstrated increased
trabecular bone (Fig. 5D–E), and static histomorphometry values
showed concordance with previous mCT-measured parameters
(Fig. 5F-BV/TV and Tb. N). The decrease in trabecular TMD
suggested a potential defect in osteoblast function, but quantifi-
cation of osteoblast numbers showed no significant differences
between the three genotypes (Fig. 5F–N. OB/BS). Furthermore,
both CD68
+/2 and CD68
2/2 mice showed significant increases in
mineral apposition rate (MAR) as measured by dynamic
histomorphometry of double calcein-labeled sections (Fig. 5G).
We found that wild type osteoblasts do not express CD68, which
suggests that the observed changes in mineralization are likely due
to indirect effects of CD68 ablation on osteoblast function (Fig. 6).




Given the increase in trabecular bone seen in vivo following
CD68 knockout, we next sought to determine the bone resorption
efficiency of osteoclasts differentiated in vitro. BMMs were seeded
onto bovine cortical bone slices with M-CSF and RANKL and
allowed to differentiate into mature osteoclasts over 4 days. After
an additional 3 days of resorption, cells were removed from the
bone slices, and pits were imaged using confocal microscopy
(Fig. 7A). We found that CD68
2/2 osteoclasts resorbed a
significantly smaller area than CD68-expressing osteoclasts by
quantification of images generated from multiple bone slices
(Fig. 7B). This confirmed our suspicion that CD68
2/2 osteoclasts
are less efficient at bone resorption than their CD68-expressing
counterparts.





In addition to preparing osteoclasts on bone slices to measure
their resorption efficiency, we differentiated osteoclasts from
Figure 3. BMMs from CD68
2/2 mice lack expression of CD68. (A) Vector diagram with a neomycin phosphotransferase expression cassette
(PGK-NEO) flanked by sequences with homology to targeted genomic sequence. A thymidine kinase expression cassette (PGK-TK) lies outside the
homology region of vector. (B) Structure of targeted wild type allele. A southern blot probe can hybridize to a genomic sequence outside of the
homology region. P1 and P2 are primers that specifically amplify the sequence of CD68 targetted for replacement. (C) Recombined allele with exons 1
and 2 of CD68 gene replaced with PGK-NEO. Properly targeted recombined alleles do not contain the thymidine kinase expression cassette. P3 and
P4 are primers that specifically amplify a region of PGK-NEO. (D) Tail tip extracts from each of three resultant genotypes were subjected to
genotyping PCR using P1, P2, P3, and P4. Each genotype produced a unique pattern of PCR products. (E) Lysates from BMMs from each genotype
cultured with 220 ng/mL M-CSF were immunoblotted with antibodies against CD68 and a-Tubulin. While expression of CD68 was seen in +/+ and +/2
BMMs, no CD68 could be detected in lysates from 2/2 BMMs.
doi:10.1371/journal.pone.0025838.g003
Table 1. Mouse Birth Ratios.
Sex +/+ +/2 2/2 Sex/Total
Male 0.22 0.55 0.24 0.52
Female 0.18 0.5 0.32 0.48
doi:10.1371/journal.pone.0025838.t001
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their in vitro morphology. Following differentiation, CD68
2/2
osteoclasts appear as well spread as CD68-expressing osteo-
clasts, but osteoclasts lacking CD68 demonstrate an intracellular
accumulation of vesicle-like structures that occur only rarely in
CD68-expressing osteoclasts (Fig. 8A). Following TRAP stain-
ing, we found that many of the previously well-spread CD68
2/2
osteoclasts had reduced much of their membranes to spindle-like
projections resulting in abnormally shaped cells (Fig. 8B).
Furthermore, we found that CD68
2/2 osteoclasts were more
susceptible to EDTA-induced lifting than CD68-expressing
cells. As measured by soluble TRAP activity assay, while
5364% of wild type osteoclasts remain attached to culture
plates after a 10 minute treatment with 0.02% EDTA, only
864% of CD68
2/2 osteoclasts remained attached after a
similar treatment (p,.001). These morphological and lifting
data indicate that CD68 is necessary for the health of
osteoclasts, and, in its absence, osteoclasts acquire dysfunctions
that are manifest in the form of aberrant morphology and
reduced adhesion to culture substrates.
Discussion
Although CD68 is routinely used as a histological marker of
macrophage lineage cells, its specific function(s) in these cells
remain undefined. Multiple studies have demonstrated CD68’s
oxLDL binding affinity, but its expression appears to have little
impact on the uptake of oxLDL [13,16,18]. There was evidence in
favor of a role in oxLDL uptake including surface expression of
CD68 as well as its rapid recycling between the intracellular/
endosomal compartment and cell surface [14]. Furthermore,
initial antibody-blockade studies on PMA-differentiated THP-1
macrophages showed that inhibition of CD68 reduced binding
and uptake of oxLDL [13]. Nevertheless, RNAi studies in
peritoneal macrophages and macrophage-like RAW264.7 cells,
however, suggested that CD68 inhibition does not reduce oxLDL
uptake, and forced expression of CD68 in COS-7 kidney cells did
not increase the ability of these cells to take up oxLDL [18].
Further evidence against a role for CD68 in oxLDL uptake can be
seen in CD68
2/2 peritoneal macrophages which take up oxLDL
as efficiently as CD68-expressing cells [20]. Thus, it appears that
Figure 4. CD68
2/2 mice have increased trabecular bone and decreased trabecular tissue mineral density. (A) Representative
trabecular mCT images from 6-month-old female mice of each genotype (5 mice per group). (B) mCT analysis of distal femoral trabecular bone
revealed that CD68
2/2 mice have increased bone volume (BV/TV), increased trabecular number (Tb. N), decreased trabecular spacing (Tb. Sp.) and
decreased trabecular tissue mineral density (Trabecular TMD). There was no significant difference in trabecular thickness (Tb. Th.). (C) Representative
cortical mCT images from each genotype. (D) Quantification of measured parameters. There was no significant difference between genotypes in
either cortical thickness (Ct. Th.) or cortical tissue mineral density (Cortical TMD). *, p,.05; **, p,.01. Data presented are means + standard deviation.
doi:10.1371/journal.pone.0025838.g004
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macrophages. With the apparent resolution of this controversy, the
question of CD68’s role in cells, nevertheless, remains unan-
swered. To date, there has been no demonstration of cellular
dysfunction due to CD68 inhibition, nor has there been prior
evaluation of the significance of CD68 expression by cells other
than macrophages and myeloid dendritic cells.
In this study, we examined the expression and localization of
CD68 in bone marrow macrophages and osteoclasts and
demonstrated that CD68 expression is critical to the normal
morphology and function of the osteoclasts. This represents the
first example of cellular dysfunction due to CD68 inhibition.
Consistent with its status as a marker of macrophage lineage cells,
we found expression of CD68 in both BMMs and osteoclasts, but
not osteoblasts. Though CD68 expression levels in BMMs and
osteoclasts were comparable, the migration rate CD68 from cells
treated with RANKL was accelerated, suggesting an alteration in
its glycosylation. The nature and significance of this altered
glycosylation has not been defined, though its consistent
appearance in both BMMs and macrophage-like RAW264.7 cells
is compelling. It has been shown that CD8’s glycosylation is
subject to alteration in response to inflammatory stimuli [21].
Phagocytosis, in particular, induces a change from a predomi-
nantly core 1 pattern of o-glycosylation to a core 2 state in
peritoneal macrophages [22]. This ‘‘phagocytic glycoform’’ of
CD68 has also been detected in BMMs. This alteration does not
appear to have an effect on surface expression, however, as
comparable amounts of CD68 can be detected on the surface of
macrophages treated with either M-CSF alone or M-CSF and
RANKL. This altered glycoform may, however, be related to the
Figure 5. Histological and histomorphometric analysis of CD68
+/+,
+/2, and
2/2 mice. (A) Representative formalin-fixed, paraffin-embedded
histological sections from each genotyped stained for TRAP activity and counterstained with hematoxylin at 40X magnification. (B) 400X
magnification of area defined in (A). (C) Quantification of number of osteoclasts per bone surface (N. OC/BS). There was no significant difference in N.
OC/BS between genotypes. (D) Representative 70% ethanol-fixed, plastic-embedded histological sections from each genotype stained with Goldner’s
trichrome at 40X magnification. (E) 400X magnification of area defined in (D). (F) Histomorphometric analysis of trichrome-stained sections. There was
no significant difference between genotypes in numbers of osteoblasts (N. OB/BS) per bone surface. There was a significant increase in bone volume
per total volume (BV/TV) in CD68
2/2 mice compared to CD68
+/+ animals and trabecular number (N. Tb.) in CD68
2/2 mice compared to CD68
+/+ and
CD68
+/2 animals. (G) Quantification of mineral apposition rate (MAR) via analysis of calcein double labeling. The MAR was significantly higher in
CD68
2/2 mice compared to both CD68
+/+ and CD68
+/2 animals, and MAR was significantly higher in CD68
+/2 mice compared to CD68
+/+ animals.
*, p,.05; **, p,.01. Data presented are means + standard deviation.
doi:10.1371/journal.pone.0025838.g005
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this. Further examining localization, we found that CD68 has a
dome-like distribution in osteoclasts cultured on bone slices. This
pattern arises from a concentration of CD68 along the Z-axis of
the osteoclast periphery with a more exclusively apical distribution
elsewhere.
In order to examine the significance of CD68 expression in
osteoclasts specifically and the consequences of its ablation in
whole animals in general, we used targeted genomic recombina-
tion to generate mice that lack expression of CD68. We found that
CD68
2/2 pups appear near expected Mendelian frequencies and
have no obvious physical or behavior abnormalities. Analysis of
the distal femurs of six-month-old female mice revealed that
knockout of CD68 resulted in increased trabecular bone that,
nevertheless, has a reduced TMD. The mineral apposition rate of
the knockout mice was increased, and this may relate to the
observed decrease in trabecular TMD. Rapid bone formation
could lead to insufficient mineralization, and there are examples of
this in the literature[24]. We also found that CD68
2/2 osteoclasts
differentiated in vitro demonstrated aberrant morphology including
accumulation of abnormal intracellular vesicles and increased
sensitivity to detachment forces. In addition, osteoclasts that lack
CD68 expression showed reduced bone resorption in vitro. These in
vitro abnormalities along with histological TRAP staining of femur
sections suggest that the increases in trabecular bone in vivo are due
to decreased osteoclast activity, not number. A decrease in bone
resorption with an increase in bone formation is unusual, as these
processes are often paired. There are, however, instances where
non-resorbing osteoclast can stimulate osteoblast activity[25,26]. If
this is the case for CD68 knockout mice, CD68 may prove to be a
valuable target for an antiresorptive therapy that uncouples bone
formation from bone resorption. The decreased trabecular TMD
that results from the increase in MAR is a concern, and the
biomechanical properties of bones from CD68 knockout animals
should be assessed to determine any consequences of this
reduction in TMD.
The in vitro phenotype of CD68
2/2 osteoclasts is intriguing in
that it recapitulates many of the abnormalities observed when the
vesicular trafficking of osteoclasts is perturbed. Vesicular
trafficking in osteoclasts is regulated by multiple factors including
members of the Rab family of small GTPases [27]. Inhibition of
individual Rab family members or their associated effectors
results in varying degrees of defective vesicular trafficking and
osteoclast dysfunction [28–31]. Lipid metabolism also contributes
to normal vesicular trafficking in osteoclasts. Luegmayr et al.
demonstrated that pharmacological depletion of cholesterol from
cultured osteoclasts resulted in cells with large vacuole-like
accumulations and an increased rate of apoptosis, and osteoclasts
with deficient LDL uptake demonstrated similar defects that were
rescued by cholesterol enrichment [32]. Beyond inhibition of
cholesterol uptake, sequestration of cholesterol within osteoclast
late endosomes is sufficient to disrupt vesicular trafficking and
ruffled border formation by preventing cholesterol enrichment in
the ruffled border [33]. While Rab function and lipid metabolism
likely have discrete roles in osteoclast vesicular trafficking, there is
certainly overlap between these two aspects. Rab functionality is
often dependant upon prenylation, which is a form of lipid
modification. Indeed, pharmacological inhibition of Rab ger-
anylgeranylation results in vesicular accumulation and decreased
osteoclast activity, and inhibition of farnesyl pyrophosphate
synthase, an enzyme of lipid metabolism, is a proposed
mechanism of osteoclast-inhibiting nitrogen-containing bisphos-
phonates which have been shown to disrupt vesicular trafficking
[34–36].
The morphological defects we have observed in CD68
2/2
osteoclasts, in light of the significance of lipid in vesicular
trafficking and CD68’s known LDL binding properties, makes a
role for CD68 in lipid processing and attractive possibility. While it
has been demonstrated that CD68 is not a key contributor to LDL
uptake, the uptake of lipid alone is not sufficient for the normal
function of osteoclasts. Rather than LDL uptake, CD68 may have
a role in delivery of lipids to their proper compartments or their
addition to prenylated proteins. Determination of lipid distribution
(i.e. cholesterol enrichment in the ruffled border) and GTPase
prenylation in CD68
2/2 osteoclasts will be an important step in
investigating these possibilities. Another important vesicular
trafficking event is the movement of bone-derived materials from
the ruffled border to the apical surface via the process of
transcytosis. As CD68 is arranged in a dome-like pattern proximal
to the basolateral and apical membranes, it may play a role in the
targeting of transcytosing vesicles to the apical membrane where
their contents are released. Typing of the abnormal vesicles seen in
CD68
2/2osteoclasts to determine their origin (e.g. late endo-
somes, transcytotic vesicles) is another way of exploring CD68’s
role in osteoclast trafficking. Coupled with studies of lipid
distribution, these studies should further illuminate CD68’s
function in osteoclasts and the mechanism of osteoclast dysfunc-
tion in its absence.
In our study, we have demonstrated the importance of CD68
expression in osteoclasts, and, in the process, produced a tool in
the form of the CD68 knockout mouse for examining not only the
contribution of CD68 to normal skeletal physiology, but also for
answering questions pertaining to CD68’s function(s) in other
tissues. Exploitation of CD68’s known properties have already
been shown to have therapeutic value in preclinical studies of
atherosclerosis, and future studies using CD68
2/2 mice and their
cells will hopefully shed light on new therapeutic opportunities.
Figure 6. CD68 is not expressed by osteoblasts. CD68 and b-actin
expression in mouse BMMs(MQ) cultured with 220 ng/mL M-CSF and
cultured mouse calvarial osteoblasts (OB) was determined by Western
immunoblotting. While expression of CD68 is high in BMMs, expression
of CD68 could not be detected in osteoblasts.
doi:10.1371/journal.pone.0025838.g006
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Ethics Statement
Mice were maintained and the experiments involving mice were
performed in accordance with the regulations of the University of
Alabama at Birmingham Institutional Animal Care and Use
Committee (animal protocol approval number: 100908911).
Chemical and Reagents
Chemicals were purchased from Sigma (St. Louis, MO) unless
indicated otherwise. DMEM (Cat No 10-013-CV), L-glutamine
(25-005-CI) were purchased from Mediatech. Fetal bovine serum
was purchased from Invitrogen (26140–079). Recombinant GST-
RANKL was purified as previously described [37]. Mouse M-CSF
was prepared from an M-CSF-producing cell line, CMG14–12,
which was constructed and kindly provided by Dr. Sunao
Takeshita [38]. Anti-CD68 antibody (rat monoclonal; FA-11),
RPE-conjugated anti-CD68 antibody, and RPE-conjugated Rat
non-immune IgG2a were purchased from AbD Serotec (Raleigh,
NC), anti-b-actin antibody (mouse monoclonal; AC-15) was
purchased from Sigma, anti-Fc receptor antibody (clone 2.4 G2;
sc-18867) was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA), b-tubulin (rabbit polyclonal; ab6046) was purchased
from Abcam (Cambridge, MA), and Alexa-647 conjugated anti-
rat-IgG (goat polyclonal; 4418) was purchased from Cell Signaling
Technology (Boston, MA).
Western immunoblotting
Cultured cells were lysed using cold cell lysis buffer with
protease inhibitor cocktail (Cell Signaling Technology; 9803,
5871). Lysates were spun down to pellet insoluble precipitates and
supernatant was transferred to clean tubes. Protein concentrations
were measured by the Bradford method. 4X sample buffer
(250 mM Tris; 140 mM sodium dodecyl sulfate [SDS]; 30 mM
bromophenol blue; 2% b-mercaptoethanol; 40% glycerol) was
added to protein solutions to a final concentration of 1X, and
samples were heated at 95uC for 10 min to denature proteins.
Samples were stored at 280uC prior to use.
Proteins were separated by sodium dodecyl sulfate polyacryl-
amide gel electrophoresis (SDS-PAGE; 8.5% acrylamide: bis-
acrylamide 30:1) in running buffer (25 mM Tris; 25 mM glycine;
3 mM SDS) and transferred to nitrocellulose membranes in
transfer buffer (50 mM Tris; 40 mM glycine; 1 mM SDS; 20%
methanol) using a semi-dry transfer apparatus for 30 min at 23 V.
Membranes were blocked with 5% milk in Tris-buffered saline
with .1% Tween-20 (TBS-T) for 1 hour at room temperature.
Membranes were incubated with primary antibody (CD68, 5mg/
mL; b-actin, 1mg/mL; a-Tubulin, 1mg/mL) at 4uC overnight.
Membranes were washed 3x for 10 minutes with TBS-T,
incubated with horse radish peroxidase-conjugated secondary
antibody (.1mg/mL) for 1 hour at room temperature, and washed
3x for 10 minutes with TBS-T. Antibody-labeled proteins were
detected with enhanced chemiluminescence and X-ray film.
Figure 7. CD68
2/2 osteoclasts do not efficiently resorb bone. BMMs from CD68
+/+,
+/2, and
2/2 mice were seeded onto bovine cortical bone
slices and differentiated into osteoclasts over 4 days. Differentiated osteoclasts were allowed to resorb the slices for an additional 3 days. (A)
Representative images of resorbed bone slices generated using laser scanning confocal microscopy. A pit from each image is marked with an arrow.
Scale bars are 70mm. (B) Quantification of resorbed area. Data represented as means + standard deviation. *, p,.001. 3 visual fields each from 3
separately resorbed bone slices were assessed. Data presented are means + standard deviation. Images and data are representative of 2 independent
experiments.
doi:10.1371/journal.pone.0025838.g007
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software.
Flow cytometric analysis
All incubations and centrifugations were carried out at 4uC.
1610
6 cells were fixed in solution with 4% paraformaldehyde/
PBS for 20 minutes. Fixed cells were washed 36 with PBS for
surface staining or PBS +.5% saponin for total staining, and Fc
receptors were blocked with anti-Fc receptor antibody for 30
minutes. Cells were then stained with either RPE-conjugated anti-
CD68 antibody or non-immune IgG2a for 45 minutes. Non-
permeablized cells were stained with an RPE-conjugated anti-
Actin antibody as a negative control for surface staining. After 3
more washes with PBS (+/2.5% saponin), cells were analyzed
using a Becton Dickinson SLR II analytical flow cytometer. Flow
histograms were generated using WinMDI.
In vitro osteoclastogenesis
BMMs were isolated from mouse long bones and were
maintained in a-minimal essential medium (a-MEM) containing
10% heat-inactivated FBS with M-CSF (220 ng/mL) as previously
described [39]. To generate osteoclasts from BMMs, 5610
4
adherent cells per well were plated in 24-well tissue culture plates
(7.5610
3 cells for 96-well plates) and cultured in presence of
44 ng/mL M-CSF and 100 ng/mL of purified GST-RANKL for
3–5 days. The osteoclastogenesis cultures were stained for TRAP
activity with Leukocyte Acid Phosphatase Kit (Sigma; 387-A).
Immunofluorescent staining of osteoclasts
BMMs (5610
4 cells per well) were seeded directly into the wells
of 24-well tissue culture plates or onto bone slices within 24-well
culture plates and cultured under either macrophage-maintaining
or osteoclastogenic conditions (with M-CSF only or M-CSF +
RANKL). Cells were fixed with 4% paraformaldehyde solution in
PBS for 20 minutes at room temperature. Cells were permeabi-
lized and blocked with a 0.2% BSA/0.1% saponin/PBS solution
(PBBS). Cells were incubated with anti-CD68 or non-immune
control IgG2a at a concentration of 10mg/mL in PBBS for 2 hours.
Cells were then washed three times with PBBS and incubated with
1:400 Hoescht, 1:200 Alexa-488 conjugated phalloidin, and 5mg/
mL Alexa-647 conjugated secondary antibody for 45 min. Cells
were again washed three times with PBBS before mounting with
80% glycerol in PBS. Stained cells were imaged with a Zeiss LSM
710 confocal microscope.
CD68 knockout mouse generation
CD68 targeting vector was constructed using standard molec-
ular cloning methods on a pBluescript-SK backbone. The
Figure 8. CD68
2/2 have abnormal morphology. (A) Prior to TRAP staining, osteoclasts of all three genotypes were of relatively similar size.
CD68
2/2 osteoclasts demonstrated intracellular vacuole-like structures that were not present to such an extent in CD68-expressing cells. Scale bars
are 100mm. Images are representative of 3 independent experiments. (B) During the fixation process (fixative: 25 mL citrate solution [18 mM citric
acid, 9 mM sodium citrate, 12 mM sodium chloride, pH 3.6], 68 mL acetone, 8 mL 37% formaldehyde), many CD68
2/2 osteoclasts were reduced in
size and partially detached from the culture substrate resulting in a smaller size following TRAP staining. Scale bars are 200mm. Images are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0025838.g008
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onic stem cells, and transfected cells were positively selected with
G418 and negatively selected with ganciclovir. Surviving clones
were screened via PCR and Southern blotting. Positive clones were
injected into albino C57B6/J blastocysts to generate CD68
+/2/
CD68
+/+ chimeras. Electroporation and embryonic stem cell
injection was carried out at the UAB Transgenic Mouse Facility.
Male chimeras were bred to albino C57B6/J females, and black-
coated offspring were genotyped using PCR. CD68
+/2 siblings





Ethanol-fixed femurs were embedded in polymethylmethacry-
late were scanned and using a ScanCo Medical mCT40 in the
UAB Small Animal Phenotyping Core. The following parameters
were measured using this system: BV/TV, Tb. N, Tb. Sp.,
trabecular TMD, cortical TMD, and cortical thickness.
Histological analysis
Prior to sacrifice, mice were injected subcutaneously with 100mL
20 mM calcein in PBS once and again 7 days later to label
mineralization fronts for dynamic histomorphometric analysis.
Formalin-fixed femurs were decalcified and embedded in paraffin
blocks for sectioning. Slide-mounted sections were stained for
Tartrate Resistant Acid Phosphatase activity and counterstained
with hemotoxylin. Osteoclast number per mm bone surface was
quantified using BioQuant software. 70%-ethanol fixed femurs
were embedded in plastic and were sectioned and stained with
Goldner’s trichrome. Static and dynamic histomorphometric
analaysis was performed using BioQuant software. Tissue
processing and staining was carried out by the UAB Center for
Metabolic Bone Disease Histomorphometry Core.
In vitro bone resorption assay
In vitro pit-forming assays were preformed similarly as previously
described [40]. 5610
4 adherent BMMs were seeded onto bone
slices within the wells of a 24-well culture plate under
osteoclastogenic conditions. Osteoclasts were allowed to differen-
tiate and mature over 4 days followed by an additional 3 days of
resorption. Osteoclastogenic medium was refreshed every 2 days.
At the conclusion of the resorption culture, cells were removed
from the bone slices using 0.25 M ammonium hydroxide and
mechanical agitation. Slices were washed with water and glued to
microscope slides for imaging using a Zeiss LSM 710 confocal
microscope. Resorption area as a percent of total area was
quantified from resulting images using Adobe Photoshop.
Soluble TRAP microtiter assay
Quantification of relative osteoclast number in vitro was carried
out using the microtiter method of Minkin et al [41,42].
Osteoclasts were lysed in 100mL soluble TRAP assay buffer
(50 mM Sodium Acetate pH 5.0, .5 mg/mL 4-Nitrophenyl
phosphate disodium salt [Sigma; S0942], .5% Triton X-100
[Sigma; 93443], and 10 mM L-Tartaric acid [Sigma; T109]) and
incubated at 37uC for 5 min. Reaction was stopped and
completed by addition of 50 mL .1 M NaOH. Absorbance was
read at 405 nm with a reference wavelength of 625 nm.
Statistical Analysis
All graphs were generated using Microsoft Excel. P-values were
calculated using a two-tailed Student’s t-Test.
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